Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular imaging: what can be used today.

P L Jager1, M A de Korte, M N Lub-de Hooge

  • 1Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center, Groningen, The Netherlands.

Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|December 20, 2005
PubMed
Summary

This review covers human metabolic imaging, focusing on positron emission tomography (PET) tracers for cancer. It details various tracers like [18F]FDG and radiolabeled amino acids, discussing their clinical applications and mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) visualisation: picturing the evidence of clinical benefit of clinical trial data.

ESMO real world data and digital oncology·2026
Same author

How to critically appraise and direct the trajectory of AI development and application in oncology.

ESMO real world data and digital oncology·2026
Same author

From algorithms to meaningful biomarkers: anchoring AI in clinical oncology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome.

Cancer immunology, immunotherapy : CII·2025
Same author

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Molecular Imaging

Background:

  • Metabolic processes in cancer cells are key targets for visualization.
  • Preclinical molecular imaging data is extensive, but clinical translation of novel tracers is slow.
  • Positron Emission Tomography (PET) is a crucial tool for in vivo metabolic imaging in humans.

Purpose of the Study:

  • To review currently available human metabolic imaging methods, particularly PET.
  • To discuss tracer uptake mechanisms and molecularly targeted imaging approaches.
  • To categorize and present applications of various cancer PET tracers based on literature and experience.

Main Methods:

  • Review of current literature on human metabolic imaging.
  • Focus on Positron Emission Tomography (PET) techniques.

Related Experiment Videos

  • Discussion of tracer classes: energy metabolism ([18F]FDG), protein metabolism (amino acids), DNA metabolism ([18F]FLT), cell membrane metabolism ([11C]choline), and biogenic amine metabolism ([18F]DOPA).
  • Examples of receptor-targeted imaging (HER2, somatostatin receptors).

    • Main Results:

    • Detailed discussion of general metabolic tracers including [18F]FDG, radiolabeled amino acids, [18F]FLT, and [11C]choline.
    • Exploration of specific tracers like [18F]DOPA for biogenic amine metabolism.
    • Presentation of molecularly targeted imaging examples.
    • Emphasis on the clinical application of these tracers across various cancer types.

    Conclusions:

    • Metabolic imaging, especially PET, offers valuable insights into cancer biology in humans.
    • A range of tracers targeting different metabolic pathways are available for clinical use.
    • Further development and clinical translation of innovative tracers are essential for advancing cancer diagnostics and treatment monitoring.